Bluebirdbio stock.

bluebird bio, Inc. (BLUE) Stock Price, Quote & News - Stock Analysis 3.89 +0.10 (2.64%) At close: Nov 24, 2023, 1:00 PM 3.92 +0.03 (0.77%) After-hours: Nov 24, …May 9, 2023 · As bluebird bio launches two first-in-class gene therapies and readies its third investigational gene therapy for SCD for the commercial setting, full-year 2023 cash burn is expected to be in the ... bluebird bio Submits Biologics License Application (BLA) to FDA for ...Get the latest bluebird bio Inc. (BLUE) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.CRISPR Therapeutics (CRSP-0.74%) and Bluebird Bio (BLUE 2.64%) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12 ...

Shares of Bluebird Bio (BLUE-0.78%) were crashing 23.3% lower as of 12:18 p.m. EDT on Monday. The big decline came after the company announced two negative developments in its second-quarter update.According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Gene therapy developer bluebird bio ( NASDAQ: BLUE) announced an agreement with Jefferies on Tuesday to sell shares of the company's common stock to raise $125M in gross proceeds. The transaction ...

AnaptysBio Inc. 14.20. UNCH. UNCH. Get bluebird bio Inc (BLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Linda Haig. December 4, 2023. Company. Bluebird bio Inc (NASDAQ:BLUE) has a beta value of 1.00 and has seen 5.06 million shares traded in the last trading session. The company, currently valued at $465.79M, closed the last trade at $4.26 per share which meant it gained $0.44 on the day or 11.52% during that session.SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a ...Shares of the commercial-stage gene therapy company bluebird bio ( BLUE 3.55%) are having a strong session Wednesday. The biotech's stock was up by a noteworthy 18.8% on heavy volume as of 10:41 a ...Get the latest bluebird bio, Inc. (BLUE) stock news and headlines to help you in your trading and investing decisions.

What happened. Shares of the gene therapy pioneer Bluebird Bio ( BLUE -1.04%) have been under heavy pressure this week. The biotech's stock dropped by a noteworthy 28.8% during the first three and ...

To say that biotech Bluebird Bio (BLUE 12.50%) has significantly lagged the market in the past year would be an understatement. ... Why Bluebird Bio Stock Soared 7% Higher on Tuesday.

Find the latest bluebird bio, Inc. (BLUE) stock quote, history, news and other vital information to help you with your stock trading and investing. ... bluebird bio, Inc. …Discover historical prices for BLUE stock on Yahoo Finance. View daily, weekly or monthly format back to when bluebird bio, Inc. stock was issued. Summary. bluebird works as a biotech company developing curative gene therapies to save lives. Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows ...In the second quarter, it reported revenue of just $6.9 million, an improvement over the $1.5 million recorded in the year-ago period. Bluebird was also unprofitable, with a net loss of $0.67 per ...Nov 26, 2023 · Get bluebird bio Inc (BLUE.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Nov 29, 2023 · See the latest bluebird bio Inc stock price (BLUE:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Shares of Bluebird Bio ( BLUE 0.61%) were sinking 10.4% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence. The decline came after the company ...Latest news about bluebird bio, Inc. Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating. Nov. 08. MT. Transcript : Bluebird bio, Inc., Q3 2023 Earnings Call, Nov 07, 2023. Nov. 07. CI. Earnings Flash (BLUE) BLUEBIRD BIO Reports Q3 Revenue $12.4M, vs. Street Est of $13.4M. Nov. 07.Shares Out 109.34M 10 Day Average Volume 4.55M Dividend - Dividend Yield - Beta 0.97 YTD % Change -45.23 RATIOS/PROFITABILITY EPS (TTM) -0.74 P/E (TTM) -5.09 Fwd …Bluebird Bio ( BLUE) is trending after the U.S. Food and Drug Administration (FDA) lifted its hold on the company’s sickle cell disease treatment. Bluebird Bio says it’s on track to submit a [email protected]. Investor Contacts. Courtney O’Leary. Investor Relations (978) 621-7347. [email protected]. stock quote stock sub menu. Stock ...

Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. 11. Bluebird Bio ( BLUE ): It ...

View the latest bluebird bio Inc. (BLUE) stock price, news, historical charts, analyst ratings and financial information from WSJ. bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How. bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies. In December, Bluebird Bio (BLUE 11.52%) and Structure Therapeutics (GPCR 6.97%) both have important events that could boost their stock prices in a big way. Here's what investors need to know ...Who is on bluebird bio's Insider Roster? The list of insiders at bluebird bio includes Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima, and William D Baird III. Learn more on insiders at BLUE.Another factor that may be contributing to BLUE stock gaining ground today — which jumped 17% and is up nearly 22% at time of writing — centers on possible short-squeeze speculation. According ...Stock Price Forecast. According to 9 stock analysts, the average 12-month stock price forecast for bluebird bio stock is $7.91, which predicts an increase of 108.71%. The lowest target is $3.00 and the highest is $13. On average, analysts rate bluebird bio stock as a buy.

Mar 29, 2023 · SOMERVILLE, Mass., March 29, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the fourth quarter and full year ...

Jun 29, 2023 · Bluebird Bio. Market Cap. $425M. Today's Change. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s ...

bluebird bio Inc (BLUE) stock is trading at $4.06 as of 1:23 PM on Friday, Dec 1, a gain of $0.23, or 6.15% from the previous closing price of $3.82. The stock has traded between $3.76 and $4.18 so far today. Volume today is less active than usual. So far 2,498,462 shares have traded compared to average volume of 4,012,219 shares.Even Bluebird Bio (NASDAQ:BLUE) is waiting on a US FDA decision on its sickle cell treatment, lovo-cel.With a decision date set for Dec. 20, BLUE is already gaining momentum, running from about $2 ...Conclusion - Streamlined and With 3 Shots at Approval In Next 12 Months bluebird Stock Looks Tempting. bluebird bio has experienced more than its fair share of setbacks - besides those discussed ...Nov 4, 2021 · November 04, 2021 07:00 AM Eastern Daylight Time. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- bluebird bio, Inc. (NASDAQ: BLUE) today announced the company has completed the tax-free spin-off of its ... Shares of bluebird bio BLUE have increased by 25.6% in a month compared with the industry ’s growth of 0.2%. Last month, bluebird posted better-than-expected results in the third quarter. It ...Dec 1, 2023 · 12 analysts have issued 1-year price objectives for bluebird bio's shares. Their BLUE share price targets range from $3.00 to $13.00. On average, they expect the company's share price to reach $7.62 in the next twelve months. This suggests a possible upside of 95.9% from the stock's current price. SCD (HGB-206) bluebird bio, Inc. gene therapy for sickle cell disease is investigational and not FDA-approved. Safety and efficacy have not been established. View the bluebird bio development pipeline and explore our list of gene therapy products and candidates at all development phases.Why Bluebird Bio Stock Soared 7% Higher on Tuesday. The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024. Find the latest bluebird bio, Inc. (BLUE) stock quote, history, news and other vital information to help you with your stock trading and ...Get bluebird bio Inc (BLUE.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsStocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Aug 28, 2023 · Bluebird Bio (BLUE 11.52%), a leader in gene therapy, could be a great pick for growth investors.This company has two gene therapies that the U.S. Food and Drug Administration (FDA) has approved ...

Shares of bluebird bio (BLUE Quick Quote BLUE - Free Report) have increased by 25.6% in a month compared with the industry’s growth of 0.2%.. Last month, bluebird posted better-than-expected ...Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. 11. Bluebird Bio ( BLUE ): It ...On average, Wall Street analysts predict that Bluebird Bio's share price could reach $7.55 by Nov 8, 2024. The average Bluebird Bio stock price prediction ...Instagram:https://instagram. trading futures softwareare there any rare quartersday trading with under 25klowest mortgage rates in ga Feb 24, 2023 · The market expects Bluebird Bio (BLUE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known consensus ... ZYNTEGLO is a one-time gene therapy to treat beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. β 0 /β 0: no beta-globin is produced. Non-β 0 /β 0: a reduced amount of beta-globin is produced. *In the phase 3 studies, the safety and efficacy of ZYNTEGLO was studied in patients aged 4–34 ... gwh stock forecastnyse bbdc bluebird bio, Inc. (BLUE) Stock Price, Quote, News & Analysis Black Friday is here! Get Premium + Alpha Picks for ONLY $438 $239 » BLUE bluebird bio, Inc. … stocks ex dividend this week Nov 4, 2023 · Bluebird Bio has experienced a barrage of issues in the past five years. The biotech has a potential approval on the way that could help it rebound. Even so, the company remains a risky stock to ... Nov 8, 2021 · Shares of Bluebird Bio ( BLUE 2.64%) were plunging 19.3% lower as of 3:42 p.m. EST on Monday. The sharp decline came after two analysts downgraded Bluebird. Goldman Sachs ( GS 0.15%) analyst ...